Latest Convertible Notes News

MyEco Group reported a 9% increase in FY25 sales driven by an 82% jump in MyEco branded products, alongside a strategic operational restructure aimed at cutting costs and boosting supply chain flexibility.

Flight Centre Travel Group reported a record $24.5 billion in total transaction value for FY25, yet underlying profit before tax declined nearly 10%, impacted by geopolitical and regional challenges. The company declared a fully franked 29-cent final dividend and outlined strategic investments in AI, digital transformation, and the cruise sector.

MyEco Group Ltd reported an 8.6% revenue increase to $15.7 million in FY25, driven by strong growth in its MyEco® branded products and improved margins. The company cut its net loss by nearly half, supported by operational restructuring and expanding market presence.

Matrix Composites & Engineering Ltd delivered a solid FY25 with $74.8 million revenue driven by subsea buoyancy demand, underpinning a $5.0 million underlying EBITDA. The company’s $57 million subsea order book and recent $45 million SURF awards set a promising stage for FY26 growth.

Matrix Composites & Engineering Ltd posted a 12.1% revenue decline to $74.77 million for FY25, reporting a net loss of $2.2 million as subdued drilling buoyancy markets weighed on results despite strong growth in subsea buoyancy products.

Imugene Limited reported a significant 54% reduction in net loss for FY25, driven by cost efficiencies and promising clinical progress in its immuno-oncology pipeline. The company’s lead asset, azer-cel, achieved a 79% response rate in Phase 1b trials and secured FDA Fast Track designation.

Australian Clinical Labs delivered solid FY25 financial results with revenue up 6.4% and EBIT rising 8.7%, underpinned by operational efficiencies and strategic innovation. The company’s FY26 guidance signals continued growth amid evolving market conditions and government fee pressures.

WebBeds reported a 22% rise in Total Transaction Value to nearly $5 billion for FY25, while EBITDA fell 14% amid margin pressures and higher costs. The company is targeting $10 billion TTV by FY30 with improved profitability.

Noumi Limited reported a 13% rise in adjusted operating EBITDA for FY25, driven by strong growth in its plant-based milks and dairy segments. The company has resolved legacy litigation issues and is now focused on navigating the $610 million convertible note maturity due in 2027.

Noumi Limited reported modest revenue growth and a significant rise in adjusted EBITDA for FY25, driven by its Milklab brand’s strong performance and a continued turnaround in its Dairy & Nutritionals segment. The company also resolved all legacy legal issues, positioning itself for future growth.

Noumi Limited has posted a significant $150 million loss for the year ending June 2025, driven by non-cash charges and raising questions about its financial stability.

Imricor Medical Systems reported a sharp 52% revenue decline and a 92% increase in net loss for H1 2025, offset by a $42.8 million equity raise boosting liquidity. The company is investing heavily in European sales and clinical trials while pursuing FDA approval.